Correlation Between Puma Biotechnology and Lyell Immunopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Puma Biotechnology and Lyell Immunopharma, you can compare the effects of market volatilities on Puma Biotechnology and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Lyell Immunopharma.

Diversification Opportunities for Puma Biotechnology and Lyell Immunopharma

0.27
  Correlation Coefficient

Modest diversification

The 3 months correlation between Puma and Lyell is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Puma Biotechnology and Lyell Immunopharma

Given the investment horizon of 90 days Puma Biotechnology is expected to generate 0.89 times more return on investment than Lyell Immunopharma. However, Puma Biotechnology is 1.12 times less risky than Lyell Immunopharma. It trades about 0.03 of its potential returns per unit of risk. Lyell Immunopharma is currently generating about -0.04 per unit of risk. If you would invest  315.00  in Puma Biotechnology on December 26, 2024 and sell it today you would earn a total of  10.00  from holding Puma Biotechnology or generate 3.17% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Puma Biotechnology  vs.  Lyell Immunopharma

 Performance 
       Timeline  
Puma Biotechnology 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Lyell Immunopharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's technical and fundamental indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Puma Biotechnology and Lyell Immunopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Puma Biotechnology and Lyell Immunopharma

The main advantage of trading using opposite Puma Biotechnology and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.
The idea behind Puma Biotechnology and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.